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Abstract
Purpose Oxaliplatin, an important chemotherapeutic agent in colorectal cancer, causes chemotherapy-induced peripheral neurop-
athy (CIPN), for which prophylactic or therapeutic interventions are lacking.We aimed to investigate changes in upper extremities,
activities of daily living (ADL), and health-related quality of life (HRQoL) parameters after the first chemotherapy cycle.
Methods Thirty-eight colorectal cancer patients scheduled to receive the leucovorin, 5′-fluorouracil, oxaliplatin (FOLFOX) therapy
or the capecitabine, oxaliplatin (CAPOX) therapy, participated. Patients underwent objective assessment of sensory function, mus-
cular strength, and manual dexterity and answered the European Organization for the Research and Treatment of Cancer Quality of
Life Questionnaire C30 (EORTC QLQ-C30) and the Disabilities of the Arm, Shoulder, and Hand-Disability/Symptom (DASH-DS)
questionnaires for subjective assessment. The CIPN was assessed at baseline and prior to the second drug cycle.
Results Light touch sensation in both hands worsened significantly after the first drug cycle, though no significant changes were
observed in muscular strength and manual dexterity. The QLQ-C30 analysis showed that Physical Functioning, Role
Functioning, Nausea and Vomiting, and Dyspnea were significantly worse, whereas Emotional Functioning was improved.
The DASH-DS analysis revealed significant worsening of dysfunction and subjective symptoms.
Conclusions Our results suggest that light touch sensation may worsen even in the absence of multiple chemotherapy cycles.
Even if arm and hand function (muscular strength and manual dexterity) is apparently intact, patients may experience dysfunction
and decreased HRQoL. For preserving or improving patients’ ADL and HRQoL, it is imperative to provide support at chemo-
therapy initiation.
Keywords Chemotherapy-induced peripheral neuropathy (CIPN) . Upper extremity function . Activities of daily living (ADL) .
Health-related quality of life (HRQoL) . Oxaliplatin (L-OHP) . Colorectal cancer
Introduction
The recent development of multidisciplinary therapy has led
to improved survival and reduced relapse in cancer patients.
However, chemotherapy side effects may decrease patient
health-related quality of life (HRQoL), with serious clinical
implications, such as the need for dose reduction, treatment
delays, or treatment discontinuation [1].
Oxaliplatin (L-OHP), an important chemotherapeutic agent
in colorectal cancer, causes acute and chronic chemotherapy-
induced peripheral neuropathy (CIPN). Chronic CIPN leads to
dose-limiting toxicity [2, 3], and a cumulative dose ≥ 540–
850 mg/m2 increases risk of subjective symptoms such as
numbness, and that of functional disorders which may affect
patient activities of daily living (ADL) [2–6]. Patients often
experience CIPN symptoms in their fingers [7], which can
interfere with ADL and HRQoL [8–11]. However, there is
no standardized effective therapy for prevention and treatment
of CIPN [12–18]. Commonly used measures of CIPN include
the National Cancer Institute Common Terminology Criteria
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(NCI-CTCAE) v4.0, and physician-based instruments [19].
However, CIPN symptoms are largely subjective, and the lack
of a universally recognized standard for quantifying CIPN
symptoms [17, 20–22] makes it difficult to capture changes
in sensory function, ADL, and HRQoL, in detail [23–25].
Chronic platinum-induced neuropathy is believed to manifest
as secondary axonal degeneration or axonal damage accom-
panying dorsal root ganglion neuronopathy [26–28].
Although L-OHP-induced neuropathy is sensory rather than
motor in nature, the intensity of dysfunction can impair phys-
ical functions, resulting in symptoms such as sensory ataxia
[1].
The negative influence of CIPN on upper extremity
function, ADL, and HRQoL can be detected only in
advanced stages of dysfunction. Once CIPN symptoms
occur, they usually persist for a year or more after treat-
ment termination [29–31]. In severe cases, sensory
nerve fiber damage may become irreversible [16].
Therefore, it is important that interventions or self-care
strategies are offered to patients prior to the appearance
of obvious CIPN symptoms.
We aimed to investigate changes in chronic sensory
neuropathy, manual dexterity, ADL, and HRQoL after
the first cycle of L-OHP-based chemotherapy in
colorectal cancer patients who were scheduled to receive
initial chemotherapy. We focused on the period after the
first chemotherapy cycle when CIPN symptoms were
expected to be milder, rather than during the period
when the cumulative L-OHP dose was 540–850 mg/m2
or higher, when functional disorders caused by chronic
CIPN are likely to appear.
Methods
Study design and participants
We conducted a prospective single-center observational study,
approved by the Kyoto University Graduate School and
Faculty of Medicine, Ethics Committee (E1571). Colorectal
cancer patients scheduled to receive initial chemotherapy with
the leucovorin, 5′-fluorouracil, oxaliplatin (FOLFOX) or the
capecitabine, oxaliplatin (CAPOX) therapy at the Kyoto
University Hospital were surveyed.
Study eligibility criteria included (a) diagnosis of colorectal
cancer, (b) scheduled FOLFOX or CAPOX therapy, (c) ability
to fill a questionnaire, and (d) written informed consent pro-
vided. Study exclusion criteria were (a) pre-existing neuro-
pathic disease (peripheral neuropathy and/or a disease of the
central nervous system), (b) prior chemotherapy, and (c)
unsuitability as deemed by the researchers and/or the attend-
ing physician.
Procedures
The CIPN measurements were collected before initiation of
the first chemotherapy cycle (baseline) and again before start
of the second drug cycle, to investigate changes in chronic
sensory neuropathy, manual dexterity, ADL, andHRQoL after
the first chemotherapy cycle. Following that, CIPN measure-
ments were collected 2 or 3 weeks after baseline just before
the second drug cycle depending on the regimen, because
FOLFOX therapy was administered every 2 weeks and
CAPOX therapy was administered every 3 weeks (Fig. 1).
Measures
Objective assessments
Sensory evaluation was performed by light touch sensation,
moving two-point discrimination (m2PD), and proprioceptive
sensation assessments. Motor function was evaluated by man-
ual dexterity, grip strength, and pinch strength tests.
Evaluation of sensory function
Evaluation of light touch sensation We employed the widely
used Semmes-Weinstein monofilament test (SWMT) (2.83,
3.22, 3.61, 4.31, 4.56, and 6.65 mg monofilaments)
(Aesthesio®, Precise Tactile Sensory Evaluator), to evaluate
light touch sensation [32]. The evaluation was conducted ac-
cording to the operation manual [33] by an experienced occu-
pational therapist. The testing procedure was explained to the
patients, and they were instructed to respond verbally by say-
ing Btouch^ or Byes^ when a stimulus was felt. Subsequently,
in a quiet area conducive to minimize distractions, two evalu-
ations were performed under similar conditions. Light touch
sensation was assessed in the right and left index finger pad (a
half beyond the distal interphalangeal joint). Perception levels
were interpreted based on the monofilament labels as follows:
2.83 (normal), 3.22 or 3.61 (diminished light touch), 4.31
(diminished protective sensation), 4.56 or 6.65 (loss of pro-
tective sensation), and 6.65 undetected (nonmeasurable).
Moving two-point discrimination test [34, 35] Pressure per-
ception of right and left index fingers was evaluated using a
two-point discriminator. One or two points of the discrimina-
tor were vertically pressed onto the long axis of the finger pad
until it bent slightly, were held for about 2 s, and then slowly
moved distally to the fingertip. The subject was asked whether
he/she was being touched at one point or at two points. Testing
began with 5-mm spacing between discriminator tips, which
was narrowed in a stepwise manner. The subject was required
to respond to two out of three stimuli before the distance was
recorded as the minimum separable distance between two
points.
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Evaluation of proprioceptive test The flexion and extension
movements of the metacarpophalangeal (MP) joints of the
right and left index fingers were repeated ten times passively.
A tenth and a half of normal range of motion (ROM) move-
ment was repeated five times each. The subject was asked
whether his/her MP joints were being moved to the flexion
or extension direction. The number of times the patient an-
swered correctly was recorded as the proprioceptive acuity
score.
Evaluation of motor function
Manual dexterity testWe used the Purdue Pegboard Test [36]
to evaluate manual dexterity. The number of pins a patient
could place in the holes of the relevant column using their
dominant hand and their nondominant hand in 30 s was re-
corded as a function of manual dexterity.
Grip strength test The grip strength of both hands was mea-
sured using a Smedley-type digital hand dynamometer
(TSUTSUMI) in the sitting and the elbow-extended positions.
Pinch strength test Pinch force between the index finger and
thumb of both hands (i.e., pulp pinch strength) was measured.
During the pulp pinch strength measurement with a hydraulic
pinch gauge (North Coast), the subjects were seated upright
with the elbow flexed at a 90° angle.
Subjective assessments
Subjective assessments of the ADL and HRQoL were per-
formed using the Japanese Society for Surgery of the Hand
(JSSH) version of the Disabilities of the Arm, Shoulder, and
Hand (DASH), and the European Organization for the
Research and Treatment of Cancer Quality of Life
Questionnaire C30 (EORTC QLQ-C30) version 3.
The DASH disability/symptom (DASH-DS) [37] The DASH is a
patient self-administered questionnaire to assess upper ex-
tremity dysfunction and relevant subjective symptoms during
the preceding week. The DASH-DS is part of DASH, with 30
items assessing: pain and subjective symptoms (5 items), the
degree of difficulty when performing various physical activi-
ties (21 items), and the effect of upper extremity dysfunction
on social activities (1 item), on work and daily life (1 item), on
sleep (1 item), and the psychological effect on self-image (1
item). Each item is scored on a scale of 1 to 5, for a total score
ranging from 0 to 100, calculated as per the DASH-DS scor-
ing manual. Higher scores indicate higher severity. In this
study, the total score was calculated from 29 items after ex-
cluding an item pertaining to sexual function. This informa-
tion was not obtained since it is not pertinent to upper extrem-
ity function, and in addition, would be difficult for the elderly
patient group to provide.
EORTC QLQ-C30 (version 3) The EORTC QLQ-C30 (version
3) (QLQ-C30) is a 30-item patient self-administered question-
naire assessing HRQoL [38], with a global health status/QOL
(global QOL) scale, 5 functional scales (physical functioning,
role functioning, emotional functioning, cognitive function-
ing, and social functioning), and 9 symptom scales (fatigue,
nausea and vomiting, pain, dyspnea, insomnia, appetite loss,
constipation, diarrhea, and financial difficulties). The QOL
scores were calculated as per the EORTC Scoring Manual.
Higher scores on the global QOL scale and the functional
scale indicate favorable conditions. Conversely, higher scores
on the symptom scale indicate poor conditions.
Statistical analyses
Scores from the Purdue Pegboard Test, grip strength test, and
the pinch strength test were compared using paired t tests.
Scores obtained from the Semmes-Weinstein monofilament
test, m2PD test, DASH-DS, and the QLQ-C30 were com-
pared using the Wilcoxon signed rank test. All statistical anal-
yses were performed using the IBM SPSS, ver. 20 software
(International BusinessMachines Corporation, Armonk, NY).
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Fig. 1 Schedule of CIPN
measurements
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Results
Forty-eight colorectal cancer patients scheduled to receive ini-
tial FOLFOX/CAPOX therapy at the Kyoto University
Hospital who provided informed consent and were enrolled
between November 2012 and June 2014. Ten patients were
excluded due to the following reasons: chemotherapy
discontinued during the assessment period (3), poor health
conditions (3), prior history of peripheral neuropathy or upper
extremity disorders (2); difficulty in baseline assessment (1),
and difficulty in assessment due to time constraints (1). Thirty-
eight patients who satisfied study eligibility criteria were in-
cluded in this study (Table 1).
Patient characteristics
Thirty-eight patients (22 men, 16 women) were included in
the study (median age 65 years; range 33–76 years). All pa-
tients were right-handed and received either the FOLFOX
(n = 19) or the CAPOX therapy (n = 19).
Objective assessments
All patients provided data for all items at baseline. However,
one patient did not provide data for the manual dexterity, grip
strength, or the pinch strength tests prior to the second drug
cycle due to malaise, pain, or other unfavorable health condi-
tions. Thus, the sample size differed by time point.
Evaluation of sensory function
Semmes-Weinstein monofilament testThere was a significant
difference in the median SWMT readings for the right index
finger at baseline (2.83 mg), and those prior to the second drug
cycle (3.61 mg) (p = 0.000, Table 2(a)). Likewise, the median
reading for the left index finger at baseline was 2.83mg, while
that prior to the second drug cycle was 2.83 mg, which were
also significantly different (p = 0.009).
Moving two-point discrimination test There was no statisti-
cally significant change between m2PD test values at baseline
and those prior to the second drug cycle (Table 2(b)).
Proprioceptive test There was no statistically significant
change between proprioceptive test results at baseline and
those prior to the second drug cycle (Table 2(c)).
Evaluation of motor function
Manual dexterity test There was no significant change in
manual dexterity test values at baseline and those prior to
the second drug cycle (Table 3(a)).
Grip strength testThere was no significant difference between
mean values for the right hand at baseline (28.3 ± 9.2 kg) and
those prior to the second drug cycle (28.0 ± 8.7 kg). Likewise,
the mean value for the left hand at baseline was 26.6 ± 9.1 kg,
while that prior to the second drug cycle was 26.2 ± 8.6 kg,
and this changewas not statistically significant (Table 3(b)). In
addition, 36/37 patients (97.3%) had lower mean grip strength
at any time compared to that of age- and gender-matched
individuals as per the FY2014 Survey on Physical Fitness
and Motor Abilities conducted by the Ministry of Education,
Culture, Sports, Science and Technology [39].
Pinch strength test No significant changes in pinch strength




The median DASH-DS score at baseline was 2.6, while that
prior to the second drug cycle was 5.2, showing significant
worsening of dysfunction and subjective symptoms (p =
0.007) (Table 4). There was a significant difference between
median scores for pain and subjective symptoms at baseline
Table 1 Characteristics of study subjects
Characteristics
Age (median, range) 65 (33–76)
N (%)
Gender Men 22 (57.9)
Women 16 (42.1)
Treatment Neoadjuvant 12 (31.6)
Adjuvant 15 (39.5)
Palliative 11 (28.9)
Regimen FOLFOX 19 (50.0)
CAPOX 19 (50.0)




Location of tumor Ascending colon 8 (21.1)
Transverse colon 7 (18.4)
Descending colon 1 (2.6)
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(median score 5), and that prior to the second drug cycle
(median score 6) (p = 0.036).
QLQ-C30
The scores for each QLQ-C30 scale were compared between
baseline and prior to the second drug cycle (Table 5). There
were no significant changes in the scores on the global health
status/QOL scale. However, physical functioning (p = 0.049)
and role functioning (p = 0.014) significantly worsened.
However, emotional functioning improved significantly (p =
0.003). Cognitive functioning and social functioning did not
change significantly. Nausea and vomiting (p = 0.045) and
dyspnea (p = 0.020) significantly worsened. There were no
significant changes in fatigue, pain, insomnia, appetite loss,
constipation, diarrhea, and financial difficulties.
Discussion
This study examined the changes in sensory dysfunction,
manual dexterity, ADL, and HRQoL after the first chemother-
apy drug cycle in colorectal cancer patients from both objec-
tive and subjective points of view, by combining six assess-
ment tools on upper extremity function and two subjective
assessment tools on ADL and HRQoL.
In this study, light touch sensation worsened after the first
drug cycle, but neither m2PD nor proprioception showed clear
worsening. The light touch sensation receptor is a slow-adapting
mechanoreceptor that affects grip force adjustment ability such
as while continuously holding an object without squashing or
dropping it. On the other hand, the m2PD receptor is a quick-
adapting mechanoreceptor that affects the identification of ma-
terials and dexterity. Thus, our results imply that slow-adapting
mechanoreceptors aremore likely to be damaged than are quick-
Table 2 Assessment of sensory
function Baseline Prior to the second drug cycle
25% Median 75% 25% Median 75% z p
(a) Semmes-Weinstein monofilament test (mg) (N = 38)
Right hand 2.83 2.83 2.83 2.83 3.61 3.61 − 4.053 0.000*
Left hand 2.83 2.83 3.32 2.83 2.83 3.61 − 2.619 0.009*
(b) Moving two-point discrimination test (mm) (N = 38)
Right hand 2.00 3.00 3.00 2.00 3.00 3.00 − 0.229 0.819
Left hand 2.00 3.00 3.00 2.00 2.00 3.00 − 0.785 0.433
(c) Propriceptive test (trials) (N = 38)
Right hand 10.00 10.00 10.00 10.00 10.00 10.00 0.000 1.000
Left hand 10.00 10.00 10.00 10.00 10.00 10.00 0.000 1.000
Wilcoxon signed rank test, *p < 0.05
Table 3 Assessment of motor
function Baseline Prior to the second drug cycle
Mean SD Mean SD t p
(a) Changes in the results of manual dexterity test (pins) (N = 37)
Right hand 14.22 2.213 14.38 1.861 − 0.589 0.560
Left hand 13.22 1.858 13.57 1.951 − 1.412 0.166
(b) Changes in the results of the grip strength test (kg) (N = 37)
Right hand 28.27 9.204 28.02 8.653 0.450 0.655
Left hand 26.61 9.098 26.24 8.602 0.744 0.462
(c) Changes in the results of the pinch strength test (N) (N = 37)
Right hand 33.54 16.77 32.65 15.46 0.550 0.586
Left hand 30.80 15.75 29.51 15.01 0.736 0.467
Paired t tests, *p < 0.05
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adaptingmechanoreceptors, during low total dose of chemother-
apy. Thus, manual dexterity, dependent on quick-adapting
mechanoreceptors did not worsen, while light touch sensation,
a function of slow-adapting mechanoreceptors worsened, in our
study. However, studies suggest that sensory ataxia may occur
as symptoms become severe [1]. Thus, as the total L-OHP dose
increases, both the slow and the quick-adapting mechanorecep-
tors may be damaged. Therefore, continuous assessments of
sensory function and manual dexterity are indicated. The signif-
icant change in the SWMT median for the right hand (2.83 vs.
3.61 mg) suggests clinically relevant dysfunction because the
perception level changes from Bnormal^ to Bdiminished light
touch.^ However, the median left hand scores at baseline and
at follow-up were similar, implying absence of clinically rele-
vant dysfunction. The 75th percentile of SWMT scores before
the second course of chemotherapy was 3.61 mg. These results
indicate that an increase in patients with diminished light touch
in the left hand as well. We cannot ascertain if this left hand
dysfunction is clinically relevant based on these results alone, so
there is a need to investigate the correlation between these results
and everyday life as a topic for future research.
L-OHP-induced peripheral neuropathy symptoms are not
considered to be due to motor neuropathy [40]. This is
consistent with the findings of this study which indicated that
motor function did not worsen after one cycle of chemother-
apy. On the other hand, the mean grip strength test score in
97.3% of patients was lower than that in age- and gender-
matched subjects according to the FY2014 Survey on
Physical Fitness and Motor Abilities [39], suggesting a lower
muscle strength in colorectal cancer patients receiving chemo-
therapy. There were 12 patients receiving neoadjuvant therapy
(31.6%), 15 patients receiving adjuvant therapy (39.5%), and
11 patients receiving palliative therapy (28.9%) in this study.
In 52.6% of patients with advanced stage IV disease with
distant metastasis, there was a risk of reduced physical
function due to disease progression in addition to that due to
chemotherapy side effects. Because this study examined
changes in chronic sensory dysfunction, manual dexterity,
ADL, and HRQoL after the first chemotherapy cycle,
Table 5 The results of the QLQ-C30 (version 3) (N = 38)
Baseline Prior to the
second drug
cycle
Mean SD Mean SD z p
Global QOL 64.0 24.2 63.2 22.1 − 0.657 0.511
Functional scales
Physical functioning 91.6 12.8 86.8 13.6 − 1.969 0.049*
Role functioning 91.7 19.3 83.8 21.4 − 2.451 0.014*
Emotional functioning 79.6 18.6 87.2 16.8 − 2.937 0.003*
Cognitive functioning 85.1 13.9 85.5 13.5 − 0.334 0.739
Social functioning 79.4 25.2 78.9 24.4 − 0.245 0.807
Symptom scales/items
Fatigue 23.4 21.1 26.9 21.9 − 0.950 0.342
Nausea/vomiting 1.8 5.2 5.7 12.4 − 2.008 0.045*
Pain 11.4 19.8 8.8 13.3 − 0.634 0.526
Dyspnea 7.9 14.4 15.8 21.6 − 2.324 0.020*
Insomnia 14.0 18.4 14.0 26.4 − 0.675 0.500
Appetite loss 13.2 22.6 14.9 25.3 − 0.472 0.637
Constipation 9.6 15.3 12.3 18.0 − 0.728 0.467
Diarrhea 20.2 23.9 18.4 22.9 − 0.843 0.399
Financial difficulties 19.3 25.3 18.4 25.3 − 1.040 0.298
Wilcoxon signed rank test, *p < 0.05
Global QoL and the functional scale (physical functioning, role function-
ing, emotional functioning, cognitive functioning, and social function-
ing): Higher scores indicate better conditions. Symptom scale (fatigue,
nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation,
diarrhea, and financial difficulties): Higher scores indicate poor
conditions
Table 4 The results of the
DASH-DS (N = 38) Baseline Prior to the second drug cycle
25% Median 75% 25% Median 75% z p
DASH-DS 0.0 2.6 8.8 2.4 5.2 13.1 − 2.708 0.007*
Subjective symptoms 5.0 5.0 6.0 5.0 6.0 8.0 − 2.094 0.036*
Difficulty of ADL 20.0 23.0 29.3 21.0 25.0 32.3 − 1.806 0.071
Influence on social Activity 1.0 1.0 1.0 1.0 1.0 1.0 − 0.378 0.705
Influence on job 1.0 1.0 1.0 1.0 1.0 1.0 − 1.633 0.102
Influence on sleep 1.0 1.0 1.0 1.0 1.0 1.0 − 1.000 0.317
Psychological influence 1.0 1.0 1.0 1.0 1.0 2.0 − 1.620 0.105
Wilcoxon signed rank test, *p < 0.05
DASH-DS (range 0-100 points), pain and subjective symptoms (range 5-25 points), the degree of difficulty when
performing various physical activities (range 20-100 points), the effect of upper extremity problem on social
activities (range 1-5 points), work and daily life (range 1-5 points), sleep (range 1-5 points), and the psychological
effect on self-image (range 1-5 points)Higher scores indicate higher severity
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objective assessment tools specialized for upper extremity
function were selected. While we were unable to objectively
evaluate the possible effect of deterioration of general patient
condition on test results, it is unlikely that disease progression
or rapid deterioration of the general condition of patients had
an effect on test scores because: only patients receiving che-
motherapy for the first time were studied; included patients
were deemed testable by a doctor; the second evaluation time
point was 2–3 weeks after the first (thus still being in the initial
stage of chemotherapy); and data from patients who were
unable to be evaluated a second time were not included in this
study. However, DASH-DS and QLQ-C30 used to assess
ADL and HRQoL are not specialized for the assessment of
CIPN symptoms, and reduced physical function can affect the
scores, so these results need to be interpreted with caution.
The objective assessment results did not reveal worsening
of upper extremity function, except in the case of light touch
sensation. This implied that no causative dysfunction was de-
tected after the first drug cycle, which might affect ADL. On
the other hand, DASH-DS, a subjective assessment tool,
showed dysfunction and worsening of subjective symptoms
after the first drug cycle. Thus, the standard clinical assessment
tools for upper extremity function showed that chemotherapy
can adversely affect daily life activities and cause worsening of
subjective symptoms in cancer patients receiving chemothera-
py even at a stage where compromised muscle strength or
upper extremity dysfunction are not likely. This indicates that
it is necessary to support cancer patients on chemotherapy
from the most initial stages, even in the absence of any appar-
ent dysfunction. It is important to note that, to provide individ-
ualized support while accommodating unique symptoms and
backgrounds during treatment, care should be taken even dur-
ing the initial stages of treatment. Additionally, patients may
have decreased sensory perception post-chemotherapy initia-
tion, so it is also necessary to focus on patient education and
providing guidance for daily living, early on.
According to the EORTC QLQ-C30 scoring manual [41],
patients who reported Ba little^ change for better or worse on a
particular scale (function or symptom) had QLQ-C30 changes
of about 5 to 10. The changes in means for role functioning,
emotional functioning, and dyspnea suggest minimal changes
clinically. The QLQ-C30 assessment revealed that emotional
functioning significantly improved while physical functioning
and role functioning significantly worsened after the first drug
cycle. According to a HRQoL study conducted 1 year post-
surgery in colorectal cancer patients who did not undergo che-
motherapy, emotional functioning significantly improved
2 months post-surgery, compared with that pre-surgery [42].
These results are consistent with the findings of the present
study which showed improved emotional functioning after
the first drug cycle. However, since patients on post-operative
adjuvant therapy as well as those on pre-operative neoadjuvant
therapy or mitigation therapy were included in the current
study, these results cannot be compared with previously pub-
lished results. Previous studies [42] have not reported worsen-
ing of physical functioning or role functioning after the first
cycle of chemotherapy. Thus, worsening of physical and role
functioning may be due to changes in HRQoL at the early
stages of chemotherapy. Role functioning tools assess the de-
gree of difficulty in work, daily life, hobbies, and leisure but
cannot address specific areas of difficulty. So, in the rehabilita-
tion of cancer patients, identifying specific areas of difficulty
and offering individualized support may be important.
Although 48 colorectal cancer patients were initially en-
rolled in this study, ten withdrew due to poor physical condi-
tion, and 38 patients were included in the final analysis.
Accordingly, the results of this study are based on patients
with relatively good systemic conditions, and hence, caution
is required while interpreting the results. In addition, in this
study, the results show worsening of light touch sensation and
subjective symptoms, and changes in scores on the symptom
scale and the functional scale. The objective of this study was
to determine changes in upper limb function, ADL, and
HRQoL after initiating chemotherapy, when the total
oxaliplatin dose is still low. It is difficult to determine the
long-term prognosis based on this time results alone. While
there are functional changes during the initial stage of chemo-
therapy, it is not clear how this is related to long-term func-
tional disability. This topic will be included in our future re-
search. A possible limitation of the study is that, since multiple
statistical comparisons were made with a small sample size, a
family-wise error (type I error) may have occurred. It is im-
portant to conduct additional large-scale and long-term studies
in the future to verify the reliability of this finding.
Conclusions
Our results suggested that light touch sensation may worsen
after the first drug cycle even during low total dose chemo-
therapy. In addition, m2PD and proprioception were main-
tained, and dysfunction that can affect ADL such as reduced
manual dexterity did not occur. However, our results also
showed that L-OHP may cause worsening of ADL and
HRQoL in patient-subjective assessments. Our results imply
that it is necessary to support cancer patients on chemotherapy
from the most initial stages, even in absence of any apparent
dysfunction.
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